Head and neck cancers are a collection of cancers originating in or near the mouth, pharynx, larynx, salivary glands, nose, or sinuses. Increasing attention is focusing on EBV+ nasopharyngeal carcinoma (NPC) as Asian markets gain prominence, while the incidence of HPV+ oropharyngeal carcinoma (OPC) is rising in the Western World. Immunotherapy has emerged as a powerful tool in this field alongside targeted therapies, with ample opportunities to develop and test novel IO agents.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Head and Neck Cancers to help guide strategic and tactical commercial development decisions for market participants.